Skip to Content
Morningstar

Novo Nordisk A/S Class B NOVO B

Morningstar Rating
Unlock
Stock XCSE Rating as of
DKK 866.80 −11.90 (1.35%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Novo Nordisk's Diabetes and Obesity Market Dominance and Pipeline Innovation Support a Wide Moat

Karen Andersen

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 32% of the $50 billion-plus diabetes treatment market and roughly half of the more than $15 billion insulin market. Diabetes' prevalence is expected to soar in coming decades as a result of an increasingly overweight and aging population, and we expect Novo to maintain its wide moat as it continues to dominate in diabetes and obesity therapy innovation.

Read Full Report

Price vs Fair Value

View History
NOVO B is trading at a 54% premium.
Price
DKK 875.30
Fair Value
DKK 373.00
Uncertainty
High
1-Star Price
DKK 192.30
5-Star Price
DKK 694.00
Economic Moat
Hdfcc
Capital Allocation
Skplrxgy

Bulls Say, Bears Say

Bulls

Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.

Bears

Tresiba's strong profile in the long-acting insulin market hasn't been enough to defend it from U.S. pricing pressure due to competition from Sanofi and Lilly, and biosimilar insulins have weighed on category pricing since 2017.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NOVO B is a good fit for your portfolio.
Get 7 Days Free

Trading Information

Previous Close Price
DKK 878.70
Day Range
DKK 853.30–876.10
52-Week Range
DKK 504.40–932.00
Bid/Ask
DKK 864.60 / DKK 865.00
Market Cap
DKK 3.87 Tril
Volume/Avg
2.4 Mil / 2.7 Mil

Key Statistics

Price/Earnings (Normalized)
46.56
Price/Sales
16.77
Dividend Yield (Trailing)
1.05%
Dividend Yield (Forward)
1.44%
Total Yield
1.86%

Company Profile

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
60,000
Website
https://www.novonordisk.com

Competitors

Valuation

View More
Metric
NOVO B
SNY
LLY
Price/Earnings (Normalized)
 46.5610.0486.39
Price/Book Value
 36.271.5663.89
Price/Sales
 16.772.3819.19
Price/Cash Flow
 32.1611.6689.75
Price/Earnings
NOVO B
SNY
LLY

Financial Strength

Metric
NOVO B
SNY
LLY
Quick Ratio
 0.620.830.52
Current Ratio
 0.821.270.94
Interest Coverage
 192.1511.0314.13
Quick Ratio
NOVO B
SNY
LLY

Profitability

Metric
NOVO B
SNY
LLY
Return on Assets (Normalized)
 30.82%8.05%10.22%
Return on Equity (Normalized)
 94.27%14.38%52.03%
Return on Invested Capital (Normalized)
 72.84%10.85%19.27%
Return on Assets
NOVO B
SNY
LLY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRDvcjxsrrdPsq$554.7 Bil
VRTX
Vertex Pharmaceuticals IncFhkjkhjzKmdhpkz$103.6 Bil
REGN
Regeneron Pharmaceuticals IncDxcrczmlSgyxyz$97.8 Bil
MRNA
Moderna IncVrljspwjRwk$38.8 Bil
ARGX
argenx SE ADRHlcxtbwjzNspn$22.3 Bil
BNTX
BioNTech SE ADRTwvdxsrxGpxt$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncWclrynnlLtyjlfq$18.2 Bil
BMRN
Biomarin Pharmaceutical IncNpnsxhdrJmlvhb$17.3 Bil
RPRX
Royalty Pharma PLC Class AVxtgdvpsgXxtdjz$12.5 Bil
INCY
Incyte CorpNrxtzcxBtcdpyf$11.5 Bil

Sponsor Center